Acelot Company Profile

Background

Overview

Acelot is a biotechnology company specializing in the development of small molecules aimed at treating neurodegenerative diseases characterized by functional protein misfolding. The company leverages advanced technologies, including generative AI and molecular dynamics simulations, to restore normal protein homeostasis in conditions such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease, diabetes, and cancer.

Mission and Vision

Acelot's mission is to pioneer innovative therapies that address the underlying causes of neurodegenerative diseases by targeting misfolded proteins. The company's vision is to transform the treatment landscape for these conditions through cutting-edge drug discovery platforms and a commitment to scientific excellence.

Primary Area of Focus

The company's primary focus is on developing small molecule therapeutics that specifically target misfolded proteins, aiming to restore their normal function and halt or reverse disease progression. This approach is particularly relevant for diseases with high unmet medical needs, such as ALS and FTD.

Industry Significance

Acelot operates within the biotechnology sector, contributing to the advancement of treatments for complex neurodegenerative diseases. By addressing the root causes of these conditions, Acelot plays a crucial role in the broader effort to improve patient outcomes and quality of life.

Key Strategic Focus

Core Objectives

• Therapeutic Development: Focus on creating small molecules that can effectively target and correct misfolded proteins associated with neurodegenerative diseases.

• Technological Innovation: Utilize advanced technologies, including generative AI and molecular dynamics simulations, to enhance drug discovery processes.

• Clinical Advancement: Progress pipeline candidates through preclinical and clinical stages, aiming for regulatory approvals and market introduction.

Specific Areas of Specialization

• Protein Misfolding Diseases: Specialization in diseases where protein misfolding leads to cellular dysfunction and death, such as ALS, FTD, and Alzheimer's disease.

• Small Molecule Therapeutics: Development of orally bioavailable small molecules capable of penetrating the blood-brain barrier to reach target sites within the central nervous system.

Key Technologies Utilized

• Generative AI: Employing AI-driven models to predict and design molecules that can correct protein misfolding.

• Molecular Dynamics Simulations: Simulating molecular interactions to understand protein behavior and optimize therapeutic candidates.

• Proprietary Assays: Developing assays to screen and validate potential drug candidates effectively.

Primary Markets or Conditions Targeted

• Amyotrophic Lateral Sclerosis (ALS): Targeting misfolded TDP-43 proteins implicated in ALS pathology.

• Frontotemporal Dementia (FTD): Addressing protein misfolding associated with FTD.

• Alzheimer's Disease: Developing therapies for Alzheimer's by targeting misfolded proteins.

Financials and Funding

Funding History

Acelot has raised a total of $22 million across multiple funding rounds, including a Series A round of $8.7 million completed in December 2024.

Notable Investors

The company's funding has been supported by various investors, including the National Science Foundation.

Intended Utilization of Capital

The capital raised is intended to support the advancement of Acelot's drug discovery platform, progress pipeline candidates through preclinical and clinical stages, and expand the company's research and development capabilities.

Pipeline Development

Key Pipeline Candidates

• ACE-2223: A first-in-class, orally bioavailable small molecule designed to target misfolded TDP-43 proteins associated with ALS, FTD, and Alzheimer's disease.

Stages of Clinical Trials or Product Development

• Preclinical Stage: ACE-2223 is currently in the preclinical stage, with plans for Investigational New Drug (IND)-enabling studies in 2024.

Target Conditions

• Amyotrophic Lateral Sclerosis (ALS): Addressing TDP-43 misfolding in ALS patients.

• Frontotemporal Dementia (FTD): Targeting TDP-43 misfolding in FTD.

• Alzheimer's Disease: Developing therapies for Alzheimer's by targeting misfolded proteins.

Relevant Timelines for Anticipated Milestones

• 2024: Initiation of IND-enabling studies for ACE-2223.

Technological Platform and Innovation

Proprietary Technologies

• Generative AI Models: Utilizing AI to design molecules that can correct protein misfolding.

• Molecular Dynamics Simulations: Simulating molecular interactions to understand protein behavior and optimize therapeutic candidates.

• Proprietary Assays: Developing assays to screen and validate potential drug candidates effectively.

Significant Scientific Methods

• Pharmacophore Analysis: Examining the Joint Pharmacophore Space (JPS) to identify structural properties relevant to desired activity or binding.

• Computational Drug Design: Employing computational chemistry to design and optimize small molecule candidates against complex targets.

Leadership Team

Key Executive Profiles

• Katie Planey, PhD, MBA: Chief Executive Officer. Dr. Planey has a background in biotechnology and has co-founded and served as CTO at Mantra Bio.

• Lewis Whitehead, PhD: Senior Vice President of R&D.